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Antimicrobial stewardshipProlonged turnaround time ofNeisseria gonorrhoeae (NG) and Chlamydia trachomatis (CT) test results may delay
time to notiﬁcation and treatment of test-positive patients and result in unnecessary antimicrobial use in test-
negative patients. This quasi‐experimental study evaluated the impact of NG/CT rapid diagnostic testing (RDT)
in an urban emergency department (ED) on treatment appropriateness, time to notiﬁcation, and cost. Patients
tested in December 2013–January 2014 (traditional group, n= 200) were compared with those in December
2014–January 2015 (RDT group, n = 200). There was a signiﬁcant increase in treatment appropriateness in
the RDT group, 72.5% versus 60% (P = 0.008) and time to results notiﬁcation was signiﬁcantly faster (median
17.4 versus 51.5 hours, P = 0.010). Availability of test result prior to discharge was associated with increased
treatment appropriateness (odds ratio, 22.65 [95% conﬁdence interval, 2.86–179.68]). The RDT would save ap-
proximately $37,000 annually. These results support the use of NG/CT RDT to expand antimicrobial stewardship
efforts within the ED.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
N. gonorrhoeae (NG) and C. trachomatis (CT) are the 2most common
bacterial sexually transmitted infections (STI) which can result in
serious complications if left untreated.(Centers for Disease Control and
Prevention; Centers for Disease Control and Prevention, 2015a) In
2014, there were more than 350,000 cases of NG and 1.4 million cases
of CT reported in the United States alone (Centers for Disease Control
and Prevention). Nonculture methods, including nucleic acid ampliﬁca-
tion tests (NAAT), arewidely available for thedetection of genital NG/CT
and are the preferred diagnostic tests recommended by the Centers for
Disease Control and Prevention (CDC) (Centers for Disease Control and
Prevention, 2014). With traditional NAAT, many health care facilitiesinterest.
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This prolonged time to results impacts time to patient and partner noti-
ﬁcation as well as treatment for test-positive patients who do not re-
ceive empiric therapy. Meanwhile, excessive empiric antimicrobial use
in test-negative patients may contribute to increasing rates of antimi-
crobial resistance (U.S. Department of Health and Human Services
Centers for Disease Control and Prevention, 2014).
The emergence of widespread antimicrobial resistance is a threat to
public health. The CDC considers drug-resistant NG as an immediate
public health threat that requires urgent and aggressive action (U.S.
Department of Health and Human Services Centers for Disease Control
and Prevention, 2014). Since 1986, the CDC's Gonococcal Isolate Surveil-
lance Project has monitored NG susceptibility to different antimicrobial
therapies. Ceftriaxone and azithromycin, 2 of the last remaining antimi-
crobials with reliable coverage against NG, now demonstrate elevated
MICs (Centers for Disease Control and Prevention National Center for
HIV/AIDS, Viral Hepatitis, STD, and TB Prevention). While the percent-
age of NG isolates with decreased susceptibility to ceftriaxone peaked
at 0.4% in 2011 and stabilized in 2013 at 0.05%, continued surveillance
is warranted (Centers for Disease Control and Prevention National
Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention; Centers
for Disease Control and Prevention, 2015b). The CDC Sexually Transmit-
ted Diseases treatment guidelines recommend combination therapy for
the treatment of NG to prevent the selective pressure for resistance tothe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Prevention, 2015b).
Antimicrobial stewardship programs have been developed within
hospitals to promote optimal prescribing of antimicrobial agents in an
effort to increase efﬁcacy, improve patient safety, and reduce antimicro-
bial resistance (Dellit et al., 2007; Society for Healthcare Epidemiology
of America et al., 2012). The development of rapid diagnostic tests
(RDTs) can help to achieve these goals by providing timely detection
of infectious organisms and allowing for targeted antibiotic therapy.
The Infectious Diseases Society of America (IDSA) and Society for
Healthcare Epidemiology of America (SHEA) advocate for the use of
RDT to improve detection capabilities and to guide appropriate treat-
ment as part of an antimicrobial stewardship program. SHEA and the
IDSA also agree that investigations evaluating the development and
cost-effectiveness of RDT are a priority. A RDT NAAT for the detection
of genital NG/CT was approved in 2012. Independent analyses of the
RDT have reported equivalent sensitivity and speciﬁcity as compared
with traditional NAAT (Gaydos et al., 2013; Goldenberg et al., 2012;
Tabrizi et al., 2013). A recently published open-label, randomized, con-
trolled trial in emergency department (ED) patients found that use of
the RDT for NG/CT resulted in decreased unnecessary antibiotic expo-
sure in test-negative patients (May et al., 2016). Subjects randomized
to the RDT armwere required towait in the ED for 90minutes following
sample collection, increasing the likelihood that the patient would be
present at the time the test results became available (May et al.,
2016). This may not be feasible in a real-world setting. Additionally,
the impact of the RDT on time to patient notiﬁcation of test results or
time to appropriate treatment was not evaluated.
The purpose of this studywas to determine if implementation of NG/
CT RDT as the standard of care in the ED would improve treatment ap-
propriateness by decreasing antimicrobial exposure in test-negative pa-
tients while increasing treatment rate in test-positive patients. We
hypothesized that the implementation of the RDT would result in in-
creased treatment appropriateness for NG/CT as well as improved
time to patient notiﬁcation and decreased cost of care.
2. Materials and methods
2.1. Study design and setting
This single-center, quasi-experimental study was conducted at an
urban community teaching hospital with approximately 70,000 ED
visits per year and more than 1500 NG/CT tests performed annually in
the ED. Patients ≥15 years of age who were tested for NG/CT via the
RDT (December 2014–January 2015) were compared to a historical
control group tested using a traditional NAAT (December 2013–January
2014). Patients were excluded if theywere tested at a satellite facility or
admitted to the hospital following testing. Patients who left the ED prior
to examinationwere excluded, as a provider was unable to evaluate the
patient for empiric therapy. Patients diagnosedwith pelvic inﬂammato-
ry disease (PID) were also excluded, as treatment of PID may overlap
with NG/CT treatment despite negative test results. Institutional review
board approval with waiver of informed consent was obtained prior to
study initiation.
2.2. Preintervention testing process
Traditional testing was performed using the Gen-Probe Aptima
Combo 2 for NG/CT Assay (Hologic, Bedford, MA). Samples utilized by
the ED includedmale urine or urethral samples and female endocervical
samples. Once received by the microbiology laboratory, samples were
placed in transport media and then couriered to an off-site laboratory
for testing. The expected turnaround time from collection to results
was 24–72 hours. Results were posted by the off-site laboratory
24 hours per day as they became available. A report of all results was
reviewed once daily by ED staff.2.3. RDT validation and intervention testing process
RDT was performed using the GeneXpert CT/NG assay (Cepheid,
Sunnyvale, CA). The RDT was validated compared with the traditional
testing method with sensitivity and speciﬁcity consistent with that re-
ported by the manufacturer (Cepheid, 2015). A total of 53 patient spec-
imens were collected and tested including male and female ﬁrst-catch
urine samples, patient-collected vaginal swabs, and provider-collected
endocervical swabs. Additionally, a NG/CT veriﬁcation panel was tested
containing 17 samples: 4 strains of C. trachomatis, 2 strains of
N. gonorrhoeae, 1 strain of N. cinerea, and 1 strain of N. ﬂavenscens. The
sensitivity for CT was 100% and speciﬁcity was 100%. The sensitivity
for GC was 94% and speciﬁcity was 100%.
Samples utilized by the ED included urine specimens for males and
females, self-collected vaginal swabs, and provider-collected
endocervical swabs. Once received by themicrobiology laboratory, sam-
ples were tested immediately using the RDT. The expected time from
collection of specimen to results was approximately 120–180 minutes.
Providers were responsible for assessing if results were available prior
to patient discharge and decision to treat. Additionally, an electronic re-
port was generated for review once daily by ED staff displaying all re-
sults from the previous 24 hours.
2.4. Selection of participants
A computer-generated report from the electronic medical record
was used to retrospectively identify all patients tested for NG/CT during
the study period. Data collected included patient characteristics, testing
characteristics, antimicrobial therapy administered, initial treatment
appropriateness, time to test results, time to patient notiﬁcation of pos-
itive test results, time to appropriate treatment, and ED length of stay.
The traditional testing group consisted of 200 consecutive patients
presenting to the ED between December 1, 2013 and January 31,
2014. Patients tested for NG/CT were considered for empiric treatment
prior to discharge at provider discretion (Centers for Disease Control
and Prevention, 2015b). Once test results returned, ED staff notiﬁed pa-
tients who tested positive for NG/CT of their results and provided
counseling and education by telephone. Patients who did not receive
empiric treatment were provided with treatment either by a telephone
prescription or by request to return to the ED for parenteral antimicro-
bial administration. If a patient was unable to be contacted after 3 tele-
phone attempts, a certiﬁed letter was mailed to the patient and patient
informationwas forwarded to the county health department for follow-
up.
The RDT was implemented for ED use in October 2014. The RDT
group consisted of 200 consecutive patients presenting to the ED be-
tween December 1, 2014 and January 31, 2015. If results were available
prior to discharge, patients with positive resultswere provided notiﬁca-
tion, counseling, and treatment for NG/CTwhile in the ED. Test-negative
patients were notiﬁed and spared unnecessary antimicrobial adminis-
tration. If patients were ready for discharge prior to the completion of
RDT results, providers had the option to provide patients with empiric
treatment and allow follow-up of results after discharge. Providers
were not encouraged to delay patient discharge in order to await RDT
results. ED staff would contact patients with positive results for notiﬁca-
tion, counseling, and treatment following the same process as the tradi-
tional test. In both groups, patients were also screened and treated for
additional STIs (e.g., trichomonas) if indicated.
2.5. Outcomes
The primary end point of this study was to compare the percentage
of patients who received appropriate treatment during their index ED
visit using the traditional test versus the RDT for NG/CT. Appropriate
treatment was deﬁned as the combined end point of test-positive pa-
tients receiving antimicrobial therapy in concordance with the CDC
Table 1






Female, n (%) 160 (80) 143 (71.5) 0.047
Age, years (mean ± SD)a 29.4 ± 9.4 29.5 ± 9.5 0.981
Age category, n (%) 0.721
15–24 years 80 (40) 69 (34.5)
25–39 years 95 (47.5) 105 (52.5)
40–64 years 24 (12) 25 (12.5)
≥65 years 1 (0.5) 1 (0.5)
Race, n (%) 0.139
Caucasian 50 (25) 55 (27.5)
African American 121 (60.5) 131 (65.5)
Other 29 (14.5) 14 (7)
Pregnant, n (%) 42 (21) 24 (12) 0.022
Insurance, n (%) 0.242
None 50 (25) 17 (8.5)
Private 24 (12) 48 (24)
Medicare 10 (5) 8 (4)
Medicaid 116 (58) 127 (63.5)
Reported STI exposure at
presentation
37 (18.5) 52 (26) 0.071
Presenting symptom, n (%)
Asymptomatic 3 (1.5) 9 (4.5) 0.079
Dysuria 39 (19.5) 38 (19) 0.899
Genital discharge 115 (57.5) 95 (47.5) 0.057
Pelvic pain 35 (17.5) 29 (14.5) 0.413
Testicular pain 4 (2) 7 (3.5) 0.359
Ordering provider b 0.001
Licensed independent practitioner 200 (100) 162 (81)
Triage nurse 0 (0) 38 (19)
Appropriate treatment, n (%) 120 (60) 145 (72.5) 0.008
Time to test order, hra 1.2 ± 1.2 1.2 ± 1.0 0.612
Time to results, hrb 31.7
(9.7–105.9)
2.4 (1.5–12) b0.001
ED length of stay, hra 3.3 ± 1.6 3.1 ± 1.5 0.078
ED length of stay N120 minutes 151 (75.5) 155 (77.5) 0.637
All categorical variables compared by χ2 test.
STI = Sexually transmitted infection.
Licensed independent practitioner = physician, nurse practitioner, and physician's
assistant.
a (Mean ± SD), compared by Student's t test.
b Median (min–max), compared by Mann–Whitney U.
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treatment.
Secondary end points included time to test results, time to patient
notiﬁcation of positive test results, and time to appropriate treatment.
Time to test result was calculated as the time the laboratory received
the sample to the time that test resultswere uploaded to themedical re-
cord. Time to patient notiﬁcation of positive test results was calculated
as the time the NG/CT results became available to the time that patient
notiﬁcationwas documented in themedical record. Time to appropriate
treatment for test-positive patients was calculated as the time the NG/
CT results became available to the time that appropriate antimicrobial
therapy was provided. Provision of appropriate antimicrobial therapy
included initial medication administration in the ED, readmission to
the ED for treatment, or a telephone prescription. A cost analysis was
performed using institutional ﬁnancial data to determine the average
cost of appropriate and inappropriate treatment in both groups. Costs
were derived using the direct cost to the institution of the test, cost of
the ED visit and revisit based on diagnosis code, and cost of
antimicrobials.
2.6. Analysis
The studywas powered to detect a 15% absolute difference in appro-
priate initial antimicrobial treatment using a 2-sided test withα=0.05
and β= 0.2. A 15% effect size was chosen based on previous literature
evaluating the integration of RDTs into antimicrobial stewardship pro-
grams (Clerc et al., 2013; Parta et al., 2010). It was determined that
167 patients in each arm would need to be included in this study. Pilot
data from the study site found that approximately 125 patients per
month were tested, therefore, 2 months were included in each group
with a maximum enrollment of 200 patients per group (n= 400).
For all baseline characteristics and study end points, categorical data
were compared using chi square or Fisher exact test; continuous data
were compared using Student's t test or theMann–WhitneyU test. Mul-
tivariate logistic regression analysis was performed to determine clini-
cally relevant variables that were independently associated with
treatment appropriateness. All variables associated with appropriate
therapy in bivariate analysis (P b 0.2) were considered for inclusion in
the multivariate model. Forward entry was used to derive the ﬁnal
model for appropriate therapy. Signiﬁcant variables in the ﬁnal model
had a P b 0.05. Statistical testing was conducted using SPSS 21.0 (SPSS,
Chicago, IL).
3. Results
3.1. Characteristics of study subjects
A total of 400 patients (200 per group)were included in the analysis.
Baseline characteristics were similar between groups (Table 1). There
were more females (80% versus 71.5%, P= 0.047) and more pregnant
patients (21% versus 12%, P=0.022) in the traditional group compared
with the RDT group, respectively. Nineteen patients (9.5%) tested posi-
tive for NG/CT in the traditional group and 20 patients (10%) tested pos-
itive in the RDT group. The overall prevalence of CT infection, NG
infection, and coinfection with NG/CT was 6.0% (n = 12), 2.0% (n =
4), and 1.5% (n = 3) in the traditional group and 7.0% (n = 14), 1.5%
(n= 3), and 1.5% (n= 3) in the RDT group, respectively.
3.2. Main results
Initial treatment was considered appropriate in 60% of patients in
the traditional group compared with 72.5% in the RDT group (P =
0.008, Table 1). This difference was driven by test-negative patients
being spared unnecessary antimicrobial therapy. For test-positive pa-
tients, empiric treatment was appropriately administered at the index
ED visit in 15 patients (78.9%) in the traditional group and 18 patients(90%) in the RDT group (P=0.407).Median time to test resultswas sig-
niﬁcantly decreased in the RDT group compared with the traditional
group (2.4 [1.4–12.0] versus 31.7 [9.7–105.9] hours, P b 0.001), as was
time to patient notiﬁcation of positive results (17.4 [0.0–93.0] versus
53.7 [26.9–79.9] hours, P = 0.010). Of note, there were 2 patients in
the traditional group (all treated empirically) and 7 in the RDT group
(5 treated empirically) who were unable to be notiﬁed of their positive
test results via telephone (P=0.092). Therewere no statistically signif-
icant differences in time to test order or in ED length of stay (Table 1).
Mean time to appropriate treatment for test-positive patients in the
traditional group was 23.0 ± 56.3 hours. Fifteen patients (78.9%) were
treated empirically at the initial ED visit and 4 (21.1%) required
follow-up for provision of treatment. Of those that required treatment
after discharge, 2 (10.5%) patients were asked to return to the ED for
treatment of NG. The mean time to appropriate treatment in the RDT
group was 4.9 ± 21.3 hours. All patients in the RDT group were treated
prior to ED discharge orwere lost to follow-up; 5 (25%)were deﬁnitive-
ly treated at the initial ED visit (positive results were available prior to
discharge and used to direct therapy), 13 (65%) were empirically treat-
ed at the initial ED visit, and 2 (10%) were unable to be contacted via
telephone and required follow-up by the county health department.
Nopatient in the RDTgroup required readmission for treatment. Testing
via RDT was associated with $4891 in cost savings ($24.46 per patient)
compared with traditional testing over the course of the study
($343,566 versus $348,457).
Ten variables were chosen for multivariate logistic regression to test
for factors independently associated with appropriate treatment
Table 2
Multivariate analysis of clinical variables associatedwith treatment appropriateness in pa-
tients tested by traditional versus RDT method.
Variable OR (95% CI) P value
Female gender 1.39 (0.74–2.62) 0.31
Pregnant 1.50 (0.76–2.98) 0.24
Medical insurance 1.15 (0.63–2.10) 0.65
Reported STI exposure 0.60 (0.34–1.06) 0.08
Complaint of genital discharge 0.42 (0.26–0.68) b0.001
Complaint of dysuria 0.89 (0.50–1.57) 0.69
Licensed independent provider ordered test 0.52 (0.21–1.33) 0.18
Length of stay N120 minutes 1.00 (0.57–1.74) 0.98
RDT 1.46 (0.89–2.39) 0.13
Results available prior to discharge 22.65 (2.86–179.68) 0.003
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ateness was availability of the NG/CT test results prior to discharge
(odds ratio [OR], 22.65 [95% conﬁdence interval {CI}, 2.86–179.68,
P= 0.003]). In total, 40 patients in the RDT group were able to be noti-
ﬁed of their test results prior to discharge. Of these patients, 5were test-
positive and 100% of these patients received appropriate treatment. Of
the 35 test-negative patients, 34were spared unnecessary antimicrobial
use. Onepatientwas treated despite having negative results because the
patient was a self-reported commercial sex worker. Patients reporting
the symptom of genital discharge were more likely to receive inappro-
priate treatment (OR, 0.42 [95% CI, 0.26–0.68, P b 0.001]).
4. Discussion
The ED presents an important area for the implementation of RDTs
to promote appropriate antibiotic use as antibiotics are prescribed fre-
quently and their downstream effects can be far-reaching. This study
found that the implementation of an RDT as the standard of care for
NG/CT testingwas associatedwith a signiﬁcant increase in antimicrobial
treatment appropriateness. Over the course of the study period, the
number of patients needed to test with the RDT to prevent 1 patient
from receiving inappropriate therapy was 8 patients. In light of the in-
creasing antimicrobial resistance of NG, these results are important as
prior literature have shown initial treatment appropriateness of NG/CT
to be low. A literature review comparing 13 studies evaluating NG/CT
testing and empiric treatment in several EDs found that 43–84% of
test-positive patients were not provided with initial empiric treatment
while 7.9–31.9% of test-negative patients were treated empirically
(Jenkins et al., 2013). A retrospective cohort evaluating 1260 women
for NG/CT in an inner city, county ED discovered that 88.3% of test-
negative patients received empiric treatment while 38.3% who tested
positive were untreated on their initial visit (Levitt et al., 2003).
There is a paucity of literature evaluating the use of RDT to improve
antimicrobial utilization in patients tested for NG/CT in any setting, in-
cluding the ED. Three studies have been published evaluating hypotheti-
cal models of NG/CT RDT in the outpatient clinic setting and its effect on
patient outcomes and cost of care. These studies showed that implemen-
tation of the RDT could likely decrease the prevalence of disease, reduce
complications, and provide signiﬁcant cost savings (Huang et al., 2013;
Hui et al., 2013; Turner et al., 2014). Recently, a randomized, controlled
trial was published comparing the use of the RDT to a standard of care
NAAT in 70 EDpatients and demonstrated improved utilization of antimi-
crobials (May et al., 2016). Our study demonstrated not only improved
appropriate antimicrobial utilization, but also improved time to patient
notiﬁcation for positive results and decreased cost of care. It is important
to note that ED length of staywas similar between the traditional andRDT
groups; therefore, utilization of the RDT did not impact ED throughput.
Additionally, the RDT resulted in cost savings. This was driven by differ-
ences in traditional testing and RDT costs ($26 versus $19, respectively),
decreased antimicrobial utilization, and decreased need for ED readmis-
sion. Extrapolated over 12 months, the RDT would save approximately$37,000 annually. These cost savings do not account for adverting PID or
other complications. Of note, this was a retrospective study, which relies
on the accuracy of documentation.
The results of this study additionally suggest that process improve-
ment should be made to optimize the utilization of the RDT within the
ED. Of the 200 patients tested in the RDT group, only 40 (20%)were pres-
ent in the EDat the time their results becameavailable. In themultivariate
logistic regression, the only factor found to positively impact treatment
appropriateness was having test results available prior to discharge
from the ED. Of note, use of the RDT alone was not independently associ-
ated with treatment appropriateness. There is often a delay in reaching a
patient for follow-up after discharge from the ED. This could potentially
result in a delay of treatment if the patient is not treated empirically, as
well as a delay to notiﬁcation and treatment of affected partners. The im-
plications of this underscore the need for rapid test results as a matter of
public health. Based on the results of this analysis, the authors have sug-
gested targeted interventions to increase the proportion of test results
available prior to discharge, including the improved utilization of a nurs-
ing triage order for NG/CT testing to increase the number of tests per-
formed before examination with a provider. Utilization of this order for
patients meeting certain criteria during the triage process may allow for
faster time to test order and processing which would increase the likeli-
hood of test results becoming available during the ED visit. We hypothe-
size that improved utilization of the RDT will result in more patients
receiving results prior to discharge, which will translate into more pa-
tients being treated appropriately and partners being notiﬁed sooner.
The only factor found to negatively impact treatment appropriateness
were patients presenting to the EDwith the symptomof genital discharge,
likely due to a large number of test-negative patients receiving empiric an-
timicrobial therapy.Whilewe recognize that the standard of care is to pro-
vide symptomatic patients with treatment for NG/CT, these patients were
classiﬁed as “inappropriately treated” for the purposes of our evaluation to
demonstrate the number of patients who could have been spared unnec-
essary antimicrobial use if RDT resultswere available prior to EDdischarge.
Additionally, there is a potential for bias anytime a new process is imple-
mented. As there were many educational updates on the NG/CT testing
process, providers may have had heightened vigilance in the RDT phase
to provide empiric treatment. The impact of temporal differences between
study periodswasminimized because the study interventionwas the only
changemade to the standard of care during this time period. Furthermore,
comparing the same time period for 2 consecutive years minimized sea-
sonal variation in the number of patients tested for NG/CT.
In conclusion, implementation of a RDT for NG/CT in the ED signiﬁ-
cantly improved initial treatment appropriateness by sparing unneces-
sary antimicrobial use, decreased time to patient notiﬁcation, and
resulted in cost savings. Having test results prior to patient discharge
from the ED was independently associated with receiving appropriate
treatment. Interventions to increase the proportion of tests resulted
prior to discharge are warranted to improve utilization of the RDT. The
ﬁndings of this evaluation support the use of the NG/CT RDT as a com-
ponent of antimicrobial stewardship in the ED.
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